A detailed history of D. E. Shaw & Co., Inc. transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 40,009 shares of RVMD stock, worth $1.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,009
Holding current value
$1.73 Million
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$36.92 - $47.94 $395,597 - $513,677
10,715 Added 36.58%
40,009 $1.81 Million
Q2 2024

Aug 14, 2024

SELL
$30.14 - $40.68 $1.34 Million - $1.8 Million
-44,363 Reduced 60.23%
29,294 $1.14 Million
Q1 2024

May 15, 2024

BUY
$26.56 - $33.55 $599,831 - $757,693
22,584 Added 44.22%
73,657 $2.37 Million
Q4 2023

Feb 14, 2024

SELL
$18.35 - $34.12 $12.7 Million - $23.7 Million
-694,198 Reduced 93.15%
51,073 $1.46 Million
Q3 2023

Nov 14, 2023

BUY
$25.17 - $35.05 $7.59 Million - $10.6 Million
301,697 Added 68.02%
745,271 $20.6 Million
Q2 2023

Aug 14, 2023

BUY
$20.28 - $27.0 $5 Million - $6.66 Million
246,741 Added 125.36%
443,574 $11.9 Million
Q1 2023

May 15, 2023

BUY
$20.76 - $30.09 $2.8 Million - $4.05 Million
134,759 Added 217.09%
196,833 $4.26 Million
Q4 2022

Feb 14, 2023

SELL
$17.68 - $25.53 $2.23 Million - $3.22 Million
-126,182 Reduced 67.03%
62,074 $1.48 Million
Q3 2022

Nov 14, 2022

BUY
$17.46 - $26.0 $3.29 Million - $4.89 Million
188,256 New
188,256 $3.71 Million
Q1 2022

May 16, 2022

SELL
$17.31 - $26.4 $338,254 - $515,882
-19,541 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$24.35 - $33.7 $475,823 - $658,531
19,541 New
19,541 $492,000
Q3 2021

Nov 15, 2021

SELL
$23.95 - $33.41 $418,933 - $584,407
-17,492 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$29.0 - $47.44 $96,193 - $157,358
-3,317 Reduced 15.94%
17,492 $555,000
Q1 2021

May 17, 2021

BUY
$37.21 - $54.43 $774,302 - $1.13 Million
20,809 New
20,809 $955,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.8B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.